MA45245A - Méthode de traitement de maladie intestinale inflammatoire - Google Patents

Méthode de traitement de maladie intestinale inflammatoire

Info

Publication number
MA45245A
MA45245A MA045245A MA45245A MA45245A MA 45245 A MA45245 A MA 45245A MA 045245 A MA045245 A MA 045245A MA 45245 A MA45245 A MA 45245A MA 45245 A MA45245 A MA 45245A
Authority
MA
Morocco
Prior art keywords
treatment
intestinal disease
inflammatory intestinal
inflammatory
disease
Prior art date
Application number
MA045245A
Other languages
English (en)
Inventor
Morris Barocas
Marc R Gastonguay
Maria Rosario
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA45245A publication Critical patent/MA45245A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045245A 2016-06-12 2017-06-12 Méthode de traitement de maladie intestinale inflammatoire MA45245A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349026P 2016-06-12 2016-06-12

Publications (1)

Publication Number Publication Date
MA45245A true MA45245A (fr) 2019-04-17

Family

ID=59270123

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045245A MA45245A (fr) 2016-06-12 2017-06-12 Méthode de traitement de maladie intestinale inflammatoire

Country Status (7)

Country Link
US (1) US11389533B2 (fr)
EP (1) EP3468597A1 (fr)
JP (1) JP7202893B2 (fr)
CN (1) CN109414502A (fr)
CA (1) CA3027286A1 (fr)
MA (1) MA45245A (fr)
WO (1) WO2017218434A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (fr) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
US20240254243A1 (en) * 2021-06-17 2024-08-01 Prometheus Laboratories Inc. Systems and methods for improved targeted therapy
KR20250037485A (ko) * 2022-07-13 2025-03-17 리제너론 파마슈티칼스 인코포레이티드 분석물 검출을 위한 약산 면역분석법
EP4720125A1 (fr) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation
EP4762093A1 (fr) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Protéines de liaison à l'intégrine alpha 4 bêta 7 et procédés d'utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2002078779A1 (fr) 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1948691A1 (fr) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L INTEGRINE a4ß7
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (fr) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
TN2017000520A1 (en) 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
EP3430052A2 (fr) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
MA43755A (fr) 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法

Also Published As

Publication number Publication date
US11389533B2 (en) 2022-07-19
JP7202893B2 (ja) 2023-01-12
JP2019519544A (ja) 2019-07-11
CN109414502A (zh) 2019-03-01
EP3468597A1 (fr) 2019-04-17
CA3027286A1 (fr) 2017-12-21
WO2017218434A1 (fr) 2017-12-21
US20190255172A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
EP3843716A4 (fr) Méthode de traitement de maladie lysosomiale
EP3538130A4 (fr) Méthode de traitement de tumeur immunothérapeutique
EP3820461A4 (fr) Méthode de traitement du cancer
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
EP2971127A4 (fr) Procédés de diagnostic et de traitement de maladie intestinale inflammatoire
EP3488001A4 (fr) Traitement du cancer
EP3463350A4 (fr) Méthode de traitement de la fibrose hépatique
EP3341080A4 (fr) Méthode de traitement du cancer
FR25C1031I2 (fr) Traitement de maladies cholestatiques intrahepatiques
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3448365A4 (fr) Méthode de traitement de la constipation
EP3455188C0 (fr) Procede de traitement de laitier
MA41462A (fr) Méthode de traitement de maladies
EP3307280A4 (fr) Traitement de dysfonction sexuelle
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3422943A4 (fr) Méthode de traitement d'intoxication médicamenteuse
EP3703707A4 (fr) Méthode de traitement de troubles de type acide-base
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
IL257764B (en) Methods for treatment of diseases